ICVX

Icosavax, Inc. (ICVX) | Rumor.io

Icosavax

ICVX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about ICVX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Dec 13

Icosavax's CVR has two components: $4 for FDA approval of its bivalent RSV/hMPV vaccine and $1 for achieving $200m sales in EU/UK/Canada.
AstraZeneca's acquisition of Icosavax for $1.1B is expected to be a significant deal in the biotech industry.
Icosavax's stock may experience a dump due to a shareholder investigation underway.

Generated by AI

Sentiment

Of the messages about ICVX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% 0
Bearish	—	—	—	0% 0

Bullish· Dec 12

Icosavax, Inc. ($ICVX) has announced positive topline interim Phase 2 results for its combination VLP vaccine candidate, solidifying its position in the vaccine development market.
The company's acquisition by AstraZeneca ($AZN) for up to $1.1B is expected to accelerate vaccine development for respiratory diseases, expanding AstraZeneca's late-stage pipeline.
$ICVX shares have jumped 45% following the acquisition, with some analysts predicting further growth as the company is poised to push higher, potentially reaching new highs near the buyout figure.

Bearish· Dec 16

$ICVX has a high chance of seeing new lows and further price drops if volume remains strong.
Icosavax Inc. is likely to dilute its shares in the overpriced market due to its ineffective $400 million shelf offer and ongoing financial struggles.
The company's stock value is expected to have a sharp negative trend in the short term and a dramatic negative long-term outlook.

Generated by AI

Topics

Of the messages about ICVX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	0%	0%
Announcements	100%	100%	100%	100%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%
Technical Analysis	0%	0%	0%	0%

Analysts· Aug 23

Multiple firms initiated coverage on Icosavax with bullish ratings and price targets, including Evercore ISI Group, Jefferies, Cowen, and William Blair.
Analysts at these firms assigned price targets ranging from $45.70 to $50 for Icosavax shares.
Icosavax received "outperform" ratings from analysts at Cowen, William Blair, and Evercore ISI Group, with some firms also assigning a "buy" rating.

Announcements· Dec 12

AstraZeneca (AZN) has agreed to acquire Icosavax (ICVX) for up to $1.1 billion, with ICVX shareholders receiving $15 per share in cash plus a $5 contingent value right.
The acquisition is expected to close in the first quarter of 2024, subject to certain conditions and regulatory clearances, and will add Icosavax's RSV vaccine candidate to AstraZeneca's pipeline.
Icosavax's shares have surged 48.2% pre-announcement, and the company's vaccine candidate has shown positive topline interim Phase 2 results for combination VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults.

Technical Analysis· Dec 15

$ICVX has formed a possible bull flag, with higher lows and MAs catching up, potentially leading to a push above $13.46.
The stock's RSI is extremely overbought at 95, indicating it may be due for a pullback or drop to $5.
$ICVX has been riding the 9-Day EMA all day, and bouncing off the 5mins ema8, suggesting a possible squeeze if it holds above $13.46.

Generated by AI

Community

Of the messages about ICVX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	99.61%
Newcomers	0%	0%	0%	0.39%

Regulars· Dec 12

Icosavax's IVX-A12 vaccine candidate has shown positive topline interim Phase 2 results against RSV and hMPV in older adults.
AstraZeneca's acquisition of Icosavax for over $800M may have been driven by the vaccine developer's robust results to date and the potential for a bid war if the data were publicly released.
Icosavax's shares have surged 45% after the acquisition, with the company's shares jumping 45% premarket.

Newcomers· Dec 12

AstraZeneca has acquired Icosavax for $15 per share plus a $5 CVR, or up to $1.1 billion.
Icosavax's Phase 2 results for its combination VLP vaccine candidate were positive, with interim results showing promise for the RSV/hMPV vaccine.
The acquisition of Icosavax by AstraZeneca is seen as a strategic move, with the company's vaccine candidate and technology potentially valuable assets for the pharmaceutical giant.

Generated by AI

Also Discussed

Investors talking about ICVX also mention

#	Name	Attention
1	AMAM - Ambrx Biopharma Inc.	——
2	Pharvaris N.V. Ordinary SharesPHVS	0%0
3	Oric Pharmaceuticals, Inc.ORIC	0%0
4	HARP - Harpoon Therapeutics, Inc.	——
5	Acumen Pharmaceuticals, Inc.ABOS	0%new
6	IGMS - IGM Biosciences, Inc.	——
7	DAWN - Day One Biopharmaceuticals, Inc.	——
8	Jasper Therapeutics, Inc.JSPR	0%0
9	Ensysce Biosciences, Inc. Common StockENSC	0%0
10	Prenetics Global Limited Class A Ordinary SharePRE	0%new

Icosavax, Inc.

Location

Social

What share of all stock conversation is about ICVX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Dec 13

Icosavax's CVR has two components: $4 for FDA approval of its bivalent RSV/hMPV vaccine and $1 for achieving $200m sales in EU/UK/Canada.
AstraZeneca's acquisition of Icosavax for $1.1B is expected to be a significant deal in the biotech industry.
Icosavax's stock may experience a dump due to a shareholder investigation underway.

Generated by AI

Sentiment

Of the messages about ICVX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% 0
Bearish	—	—	—	0% 0

Bullish· Dec 12

Icosavax, Inc. ($ICVX) has announced positive topline interim Phase 2 results for its combination VLP vaccine candidate, solidifying its position in the vaccine development market.
The company's acquisition by AstraZeneca ($AZN) for up to $1.1B is expected to accelerate vaccine development for respiratory diseases, expanding AstraZeneca's late-stage pipeline.
$ICVX shares have jumped 45% following the acquisition, with some analysts predicting further growth as the company is poised to push higher, potentially reaching new highs near the buyout figure.

Bearish· Dec 16

$ICVX has a high chance of seeing new lows and further price drops if volume remains strong.
Icosavax Inc. is likely to dilute its shares in the overpriced market due to its ineffective $400 million shelf offer and ongoing financial struggles.
The company's stock value is expected to have a sharp negative trend in the short term and a dramatic negative long-term outlook.

Generated by AI

Topics

Of the messages about ICVX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	0%	0%
Announcements	100%	100%	100%	100%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%
Technical Analysis	0%	0%	0%	0%

Analysts· Aug 23

Multiple firms initiated coverage on Icosavax with bullish ratings and price targets, including Evercore ISI Group, Jefferies, Cowen, and William Blair.
Analysts at these firms assigned price targets ranging from $45.70 to $50 for Icosavax shares.
Icosavax received "outperform" ratings from analysts at Cowen, William Blair, and Evercore ISI Group, with some firms also assigning a "buy" rating.

Announcements· Dec 12

AstraZeneca (AZN) has agreed to acquire Icosavax (ICVX) for up to $1.1 billion, with ICVX shareholders receiving $15 per share in cash plus a $5 contingent value right.
The acquisition is expected to close in the first quarter of 2024, subject to certain conditions and regulatory clearances, and will add Icosavax's RSV vaccine candidate to AstraZeneca's pipeline.
Icosavax's shares have surged 48.2% pre-announcement, and the company's vaccine candidate has shown positive topline interim Phase 2 results for combination VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults.

Technical Analysis· Dec 15

$ICVX has formed a possible bull flag, with higher lows and MAs catching up, potentially leading to a push above $13.46.
The stock's RSI is extremely overbought at 95, indicating it may be due for a pullback or drop to $5.
$ICVX has been riding the 9-Day EMA all day, and bouncing off the 5mins ema8, suggesting a possible squeeze if it holds above $13.46.

Generated by AI

Community

Of the messages about ICVX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	99.61%
Newcomers	0%	0%	0%	0.39%

Regulars· Dec 12

Icosavax's IVX-A12 vaccine candidate has shown positive topline interim Phase 2 results against RSV and hMPV in older adults.
AstraZeneca's acquisition of Icosavax for over $800M may have been driven by the vaccine developer's robust results to date and the potential for a bid war if the data were publicly released.
Icosavax's shares have surged 45% after the acquisition, with the company's shares jumping 45% premarket.

Newcomers· Dec 12

AstraZeneca has acquired Icosavax for $15 per share plus a $5 CVR, or up to $1.1 billion.
Icosavax's Phase 2 results for its combination VLP vaccine candidate were positive, with interim results showing promise for the RSV/hMPV vaccine.
The acquisition of Icosavax by AstraZeneca is seen as a strategic move, with the company's vaccine candidate and technology potentially valuable assets for the pharmaceutical giant.

Generated by AI

Icosavax

Social

Dec 13

Sentiment

Bullish· Dec 12

Bearish· Dec 16

Topics

Analysts· Aug 23

Announcements· Dec 12

Technical Analysis· Dec 15

Community

Regulars· Dec 12

Newcomers· Dec 12

Also Discussed

Icosavax, Inc.

Company Information

Location

Also Discussed

Social

Dec 13

Sentiment

Bullish· Dec 12

Bearish· Dec 16

Topics

Analysts· Aug 23

Announcements· Dec 12

Technical Analysis· Dec 15

Community

Regulars· Dec 12

Newcomers· Dec 12